High Gross Margins & Low LeverageA ~99% gross margin reflects a licensing/royalty business mix that sustains high unit economics long-term, while minimal TTM debt (~$0.35M) preserves financial optionality. Together these structural features reduce near-term liquidity stress and support funding of R&D without heavy interest burden.
Clear IND/Phase I Development TimelinesDefinitive IND and Phase I schedules for both an oral small molecule and a once-weekly peptide materially de-risk early execution. Clear milestone pacing enables resource allocation, fundraising planning, and creates multiple discrete value-inflection points tied to clinical data rather than speculative timelines.
Strengthened Cash Position And RunwayThe recent $18.2M financing and a $14.5M cash balance provide multiquarter runway to fund planned Phase I programs. This reduces immediate financing pressure, supports disciplined progression of clinical work, and gives management time to generate IND/early clinical value before needing further dilutive capital.